Validation of Bispectral Index (BIS)-Monitor in 3 Groups of Newborn Children
Validation of BIS-monitor in 3 Groups of Newborn Children
1 other identifier
observational
24
1 country
1
Brief Summary
This study will evaluate the registration of the bispectral index and spectral edge frequency in relation to the behavioural state.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2003
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2004
CompletedFirst Submitted
Initial submission to the registry
August 25, 2005
CompletedFirst Posted
Study publicly available on registry
August 26, 2005
CompletedDecember 22, 2022
December 1, 2022
1.4 years
August 25, 2005
December 21, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Validation of the Bispectral Index(BIS)-Monitor
Validation of the Bispectral Index(BIS)-Monitor by registration of the bispectral index and spectral edge frequency in relation to behavioural state
Short after birth of the newborn
Study Arms (3)
Normal healthy term newborn
Normal healthy term newborns
Ill term newly born without brain damage
Ill term newly borns without brain damage
Preterm newly born without brain damage
Preterm newly borns without brain damage
Interventions
Registration of the bispectral index and spectral edge frequency
Eligibility Criteria
Newborn children
You may qualify if:
- Group 1: normal healthy term newborns
- Group 2: Ill term newborns without brain damage
- Group 3: Preterm newborns without brain damage
You may not qualify if:
- Abnormal brain ultrasound
- Abnormal neurological examination
- Major congenital abnormalities
- Use of analgesics, sedatives, antiepileptic drugs or curarisation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Ghent
Ghent, 9000, Belgium
Related Links
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Claudine De Praeter, MD, PhD
University Hospital, Ghent
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2005
First Posted
August 26, 2005
Study Start
August 1, 2003
Primary Completion
December 31, 2004
Study Completion
December 31, 2004
Last Updated
December 22, 2022
Record last verified: 2022-12